ServiceNow ( NOW) rated new outperform at JMP Securities. $56 price target. Company is a cloud leader in IT Service Management. Pharmacyclics ( PCYC) upgraded at Lazard to buy, Lazard Capital Markets said. $141 price target. Checks show a strong outlook for ibrutinib. Rowan ( RDC) upgraded at JP Morgan from neutral to overweight, JP Morgan said. Dayrates have likely bottomed. $39 price target. Select Medical ( SEM) downgraded at Wells from market perform to underperform, Wells Fargo said. Long-term acute care hospitals will face Medicare reimbursement risks in 2015. Vivus ( VVUS) downgraded at Lazard to sell, Lazard Capital Markets said. $8 price target. Qsymia has had a slow launch and the company's patents could face competition. Verizon ( VZ) upgraded at Baird from neutral to outperform, Robert Baird said. $53 price target. VZW purchase should benefit long-term positioning and earnings growth.
Abbott Laboratories ( ABT) numbers lowered at Jefferies. Shares of ABT now seen reaching $44, Jefferies said. Estimates also lowered on model adjustment. Buy rating. eBay ( EBAY) added to Best Ideas List at Wedbush. EBAY was placed on the Best Ideas list, according to Wedbush. Paypal is winning and marketplace growth is reaccelerating. Outperform rating and $64 price target. Halliburton ( HAL) estimates, target raised at Sterne Agee. Shares of HAL now seen reaching $63, according to Sterne Agee. Estimates also increased, following the company's dutch auction repurchase. Buy rating. Microsoft ( MSFT) estimates, target reduced at BMO. Shares of MSFT now seen reaching $35, according to BMO Capital. Estimates also cut, as the Nokia deal will cut into earnings.